Nathan Pennell

19PUBLICATIONS
170CO-AUTHORS
Autonomic nervous systemMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersEconomic models and forecasting
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jun 03, 2026
Progressive disability but survival advantage in anti-Hu/ANNA1 paraneoplastic neurological syndromes.

|Jan 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Sarah Waliany, Alissa J Cooper, Stephen V Liu

|Nov 20, 2025
Return to Intended Oncologic Therapy in Patients With Metastatic Non-Small Cell Lung Cancer Discharged to a Skilled Nursing Facility.

Anirudh Yalamanchali, Preeyal Patel, Ali Mushtaq

|Apr 23, 2025
Larotrectinib Compared With Real-World Non-Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer.

Marcia S Brose, C Benedikt Westphalen, Xiaoyun Pan

|Apr 03, 2025
Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST.

Maurice Pérol, Wei Li, Nathan A Pennell

|Feb 27, 2025
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do

Pageof 4

Frequent Collaborators

3 joint publications

Benjamin Besse

3 joint publications

Justin F Gainor

3 joint publications

Anant Madabhushi

2 joint publications

Natalie Vokes